Pulmonary Aspergillosis: A Review on Diagnosis and Management

Bilal A. Jalil
University of Louisville

Juan M. Galvis
University of Louisville

Karim A. El Kersh
University of Louisville

Mohamed Saad
University of Louisville

Mostafa M. Fraig
University of Louisville

See next page for additional authors

Follow this and additional works at: https://ir.library.louisville.edu/jri

Part of the Community Health and Preventive Medicine Commons, Epidemiology Commons, Health Information Technology Commons, Influenza Humans Commons, Influenza Virus Vaccines Commons, International Public Health Commons, and the Translational Medical Research Commons

Recommended Citation
Jalil, Bilal A.; Galvis, Juan M.; El Kersh, Karim A.; Saad, Mohamed; Fraig, Mostafa M.; and Guardiola, Juan J. II (2018) "Pulmonary Aspergillosis: A Review on Diagnosis and Management," The University of Louisville Journal of Respiratory Infections: Vol. 2 : Iss. 2 , Article 6.
DOI: 10.18297/jri/vol2/iss2/6
Available at: https://ir.library.louisville.edu/jri/vol2/iss2/6

This Review Article is brought to you for free and open access by ThinkIR: The University of Louisville's Institutional Repository. It has been accepted for inclusion in The University of Louisville Journal of Respiratory Infections by an authorized editor of ThinkIR: The University of Louisville's Institutional Repository. For more information, please contact thinkir@louisville.edu.
Pulmonary Aspergillosis: A Review on Diagnosis and Management

Cover Page Footnote
Corresponding Author: Bilal Jalil Pulmonary and Critical Care Fellow University of Louisville 550 S Jackson St, A3R40 Louisville, KY 40241, USA Disclosures: The authors listed do not have any pertinent financial disclosures or conflicts of interest.

Authors
Bilal A. Jalil, Juan M. Galvis, Karim A. El Kersh, Mohamed Saad, Mostafa M. Fraig, and Juan J. Guardiola II
Pulmonary Aspergillosis: A Review on Diagnosis and Management

Bilal A Jalil1*, Juan M Galvis1, Karim El-Kersh1, Mohamed Saad2, Moustafa Fraig2, Juan J Guardiola1

Abstract

Aspergillosis is acquired by inhalation of spores of Aspergillus, a ubiquitous species in the environment. In normal hosts, spore inhalation rarely causes lung disease.

Pulmonary aspergillosis covers a wide spectrum of clinical syndromes depending on the interaction between Aspergillus and the host (immune-status, prior bronchopulmonary disease). It runs the gamut from invasive aspergillosis to Aspergillus bronchitis and colonization.

Invasive aspergillosis occurs in severely immunocompromised patients, typically with neutropenia. Chronic pulmonary aspergillosis affects patients with chronic structural lung disease such as chronic obstructive pulmonary disease, mycobacterial lung disease, but without significant immunocompromise. Aspergillus bronchitis affects patients with bronchial disease such as bronchiectasis. Allergic bronchopulmonary aspergillosis affects patients with bronchial asthma or cystic fibrosis, and is due to an allergic response to Aspergillus.

In this review of literature, we discuss the pulmonary manifestations of Aspergillus infection, its diagnosis and treatments.

Introduction

Aspergillosis is a disease caused by fungi of the genus Aspergillus principally A. fumigatus, and less commonly A. flavus, A. terreus, and A. niger. The name Aspergillus is derived from its resemblance to the sporulating head of Aspergillus and the aspergillum/aspergill used to sprinkle holy water (from latin aspergere: to sprinkle.) Aspergill are filamentous saprophytic molds ubiquitous in nature that grow in soil, decaying vegetation, and water. Direct examination of Aspergillus within tissue reveals septated hyphae which dichotomously branch at 45° as shown in Figure 1.

While Aspergillus can involve a variety of organ systems, including the respiratory (lung, sinuses), central nervous, ocular, gastrointestinal/hepatic and renal systems causing significant morbidity and mortality [1, 2]. This review of literature will focus on the pulmonary manifestations of Aspergillus infections.

Aspergillus causes a spectrum of pulmonary diseases (presented in Table 1) determined by the interplay between the pathogen Aspergillus, underlying lung disease and the host immunity [3-7]. On one end of the spectrum, invasive pulmonary aspergillosis (IPA) predominantly affects patients with severe immune dysfunction, while chronic pulmonary aspergillosis (CPA) affects patients with underlying lung disease but with an absence of, or mild immune dysfunction. Acute community-acquired Aspergillus pneumonia occurs in patients without significant immune deficits and normal lungs. Aspergillus bronchitis is a chronic bronchitis that is mostly seen in non-immunocompromised patients with bronchiectasis or cystic fibrosis. Allergic bronchopulmonary aspergillosis is due to an allergic response to inhaled Aspergillus in asthmatics.

Invasive Pulmonary Aspergillosis

Acute invasive pulmonary aspergillosis (IPA) is a rapidly progressive infection that occurs in highly immunocompromised patients and carries a mortality upwards of 50 to 80%. [8, 9] The classic risk factor for IPA is neutropenia and the likelihood of IPA depends on the duration and severity of neutropenia. Histologically, IPA in neutropenic hosts shows angioinvasion (Figure 2), while IPA in non-neutropenic patients does not usually demonstrate angioinvasion and occurs in a wide range of conditions: allogeneic hematopoietic stem-cell transplantation after neutrophil recovery, solid organ transplantation, advanced AIDS, chronic granulomatous disease, and critically-ill ICU patients [10]. The most common risk factors for these patients is the use of chronic corticosteroid therapy.

IPA has been increasingly diagnosed in non-neutropenic ICU patients who have non-specific risk factors such as sepsis, chronic obstructive pulmonary disease (COPD), steroid therapy, multiple antibiotic treatments, and hepatic and/or renal failure.
Sepsis probably causes a state of ‘immunoparalysis’ and steroids cause an immunodeficient state that promotes the occurrence of IPA.

The diagnosis of IPA is based on the criteria mentioned in Table 2. Histopathologic visualization of fungal elements alone is not sensitive enough to diagnose invasive aspergillosis and should be accompanied by immunostains, cultures and where available, nucleic acid amplification tests (NAAT) [11, 12]. Assays for PCR and NAAT are not commercially available yet and require submission of samples to research or reference laboratories that have validated assays. The galactomannan assay is a fairly specific and sensitive test for the diagnosis of invasive pulmonary aspergillosis. Galactomannan is found in the cell wall of \textit{Aspergillus} species and the assay can be performed in serum, BAL and pleural fluid, although the sensitivity is higher when performed in BAL fluid than in serum. Galactomannan assay results are always used in combination with culture and histopathology results. The sensitivity of the assay increases with repeated testing (one week apart) and has the highest sensitivity among patients with hematological malignancies or post-hematopoietic stem cell transplantation [13].

False positive serum and BAL galactomannan assays can be caused by several beta-lactam antibiotics including piperacillin-tazobactam and carbapenem [14]. Galactomannan is also found in the cell walls of \textit{Histoplasma capsulatum} and \textit{Fusarium} \textit{spp}. The concurrent use of caspofungin has been associated with a higher sensitivity of the galactomannan assay likely due to the increase in galactomannan levels released from cell wall breakdown. In addition to the galactomannan, serum 1,3 beta-D-glucan test may be helpful, keeping in mind the cross-reactivity with pseudomonas can yield false positive results [13].

**Treatment of IPA**

Voriconazole is the recommended primary therapy for IPA based on a randomized trial that compared voriconazole with amphotericin B deoxycholate and showed improved survival with voriconazole [16]. Voriconazole can be given intravenously or orally. Alternative primary therapies are liposomal amphotericin B and isavuconazolium. Recently, the FDA has approved isavuconazolium (a pro-drug of isavuconazole) for intravenous and oral treatment of IPA[17]. The recommendation was based on a randomized trial of isavuconazolium vs voriconazole. All-cause mortality and overall response rates

---

**Table 1. Spectrum of Diseases Caused by Aspergillus adapted from Denning et al [3]. (HSCT = Hematopoietic stem-cell transplant; CGD = Chronic granulomatous disease).**

<table>
<thead>
<tr>
<th>Aspergillus syndromes</th>
<th>Immune Status</th>
<th>Underlying Lung Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Invasive Pulmonary Aspergilosis (IPA)</strong></td>
<td>Immunocompromised host</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>a. Prolonged and profound neutropenia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>b. Non-neutropenic: Corticosteroids, HIV/AIDS, HSCT recipient, solid organ transplant, CGD</td>
<td></td>
</tr>
<tr>
<td><strong>Tracheobronchial Aspergilosis (TBA)</strong></td>
<td>Immunocompromised host (AIDS, post-transplant)</td>
<td>Lung transplant</td>
</tr>
<tr>
<td><strong>Chronic Pulmonary Aspergilosis (CPA)</strong></td>
<td>Non-immunocompromised host</td>
<td>Emphysema, previous cavitary tuberculosis</td>
</tr>
<tr>
<td>Chronic cavitary CPA, fibrosing CPA, aspergilloma, and nodule(s)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Aspergillus bronchitis</strong></td>
<td>Non-immunocompromised host</td>
<td>Bronchiectasis</td>
</tr>
<tr>
<td><strong>Acute Community-Acquired Aspergillus Pneumonia</strong></td>
<td>Non-immunocompromised host</td>
<td>Normal lungs/post-influenza</td>
</tr>
<tr>
<td><strong>Allergic Bronchoalimentary Aspergilosis (ABPA)</strong></td>
<td>Non-immunocompromised host hypersensitivity to Aspergillus</td>
<td>Asthma, cystic fibrosis</td>
</tr>
</tbody>
</table>

---

**Figure 1.** A photomicrograph of lung tissue on autopsy showing \textit{Aspergillus} hyphae with acute angle branching on H&E stain.

**Figure 2.** A photomicrograph of lung tissue on autopsy showing angioinvasion by \textit{Aspergillus} on H&E stain.
Table 2. Diagnostic criteria for invasive pulmonary aspergillosis per the European Organization for the Research and Treatment of Cancer (EORTC) and the Mycosis Study Group [15].

<table>
<thead>
<tr>
<th>Proven Invasive Pulmonary Aspergillosis</th>
<th>Probable Invasive Pulmonary Aspergillosis</th>
<th>Possible Invasive Pulmonary Aspergillosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Sterile biopsy showing hyphae branching at 45° (morphologically suggestive of Aspergillus) with evidence of associated tissue damage  <strong>OR</strong>  • Aspergillus on culture of lung biopsy specimens</td>
<td>Clinical criteria (one of the following):  • Recent history of neutropenia (absolute neutrophil count &lt; 500 cells)  • Allogeneic stem-cell transplant recipient  • Prolonged corticosteroid exposure (mean dose &gt; 0.3 mg/kg/day of prednisone equivalent for 13 weeks)  • Therapy with known T-cell immunosuppressive agents (e.g. Cyclosporine, tacrolimus, etc.)  • Hereditary severe immunodeficiency  <strong>AND</strong>  Radiologic criteria on CT (one of the following):  • Well-circumscribed, dense lesions ± halo sign  • Air-crescent sign  • Cavitary lesion  <strong>AND</strong>  Mycological criteria (one of the following):  • Cytology, culture or microscopy of respiratory sample (BAL, bronchial brush) showing fungal elements or growing Aspergillus  • Detection of antigen or cell-wall components (e.g. Galactomannan in serum, plasma or BAL)</td>
<td>Clinical criteria (one of the following):  • Recent history of neutropenia (absolute neutrophil count &lt; 500 cells)  • Allogeneic stem-cell transplant recipient  • Prolonged corticosteroid exposure (mean dose &gt; 0.3 mg/kg/day of prednisone equivalent for 13 weeks)  • Therapy with known T-cell immunosuppressive agents (e.g. Cyclosporine, tacrolimus, etc.)  • Hereditary severe immunodeficiency  <strong>AND</strong>  Radiologic criteria on CT (one of the following):  • Well-circumscribed, dense lesions ± halo sign  • Air-crescent sign  • Cavitary lesion  <strong>AND</strong>  Prolonged corticosteroid exposure (mean dose &gt; 0.3 mg/kg/day of prednisone equivalent for 13 weeks)  <strong>AND</strong>  Therapy with known T-cell immunosuppressive agents (e.g. Cyclosporine, tacrolimus, etc.)  <strong>AND</strong>  Hereditary severe immunodeficiency  <strong>AND</strong>  Serial testing of beta-D-glucan and galactomannan may improve sensitivity and specificity</td>
</tr>
</tbody>
</table>

were similar in both groups.

Patients who do not respond to monotherapy are considered for combination antifungal therapy usually with an echinocandin in addition to voriconazole or liposomal amphotericin B. The treatment of IPA should be continued for a minimum of 6 to 12 weeks, dependent on the duration and severity of immunosuppression and the clinical response to therapy [18].

Tracheobronchial Aspergillosis (TBA)

Tracheobronchial aspergillosis is a unique feature of IPA, representing isolated tracheobronchial invasion. Predisposing factors for TBA are similar to those for IPA, however it has been mainly described in lung transplantation recipients, and patients with AIDS. The diagnosis requires bronchoscopy. TBA has been classified into 3 forms (19). Obstructive TBA manifests as thick mucus plugs loaded with Aspergillus spp. without obvious bronchial inflammation. Pseudomembranous TBA is characterized by extensive involvement of the tracheobronchial tree with a membranous slough overlying the mucosa containing Aspergillus as shown in Figure 3.

Ulcerative TBA is a focal process usually found at the suture line of the tracheobronchial Anastomosis in lung transplant recipients. The diagnosis of TBA is usually made by the characteristic findings on bronchoscopy (Figure 4) combined with microbiological and pathological analysis of the respiratory specimens obtained during bronchoscopy.

Treatment of TBA

Similar to IPA, voriconazole or lipid formulation of amphotericin B is used. Bronchoscopic debridement of airway lesions and minimization of immunosuppression when feasible are also considered [20]. In lung transplant recipients with anastomotic TBA, adjunctive inhaled amphotericin B is recommended. The duration of antifungal therapy is at least 3 months, or until TBA has completely resolved.

Neutropenic Fever in Patients with Cancer

Neutropenic patients can be classified as high-risk or low-risk [21]. Patients with any of the following are considered high-risk if they have:

- profound neutropenia (ANC < 100 cells/m3), anticipated to be prolonged (> 7 days), and
- the presence of medical comorbidities: hemodynamic instability, oral mucositis causing dysphagia, gastrointestinal symptoms (abdominal pain, nausea, vomiting or diarrhea), new-onset neurologic changes, pneumonia, intravascular catheter infections [21].
High-risk patients who have received intensive cytotoxic chemotherapy are at risk for “invasive” fungal infections; yeasts (primarily Candida species) and molds (primarily Aspergillus). They typically cause persistent or recurrent fever in patients with profound (≤ 100 cells/mm³) and prolonged (> 10-15 days) neutropenia. Fever may be the only sign in the early stages of fungal infections.

The Infectious Diseases Society of America (IDSA) recommends empiric antifungal therapy for high-risk neutropenia in patients with persistent or recurrent fever after 4-7 days of empirical broad spectrum antibiotic therapy [21].

**Chronic Pulmonary Aspergillosis (CPA)**

There are a multitude of chronic forms of CPA that may overlap as illustrated in Figure 5. The progression of CPA is slow with a duration of at least 3 months. It affects patients with underlying chronic lung conditions, namely tuberculous and non-tuberculous mycobacterial infections, COPD, bullous lung disease, ABPA, asthma, pulmonary fibrocystic sarcoidosis, lung radiation, rheumatoid arthritis, and ankylosing spondylitis [3].

The key diagnostic test for CPA is the detection of IgG to Aspergillus (or the less sensitive serum Aspergillus precipitins). Positive anti-Aspergillus antibodies differentiate infected patients from colonized patients, with a positive predictive value of 100% for infection. Positive PCR, culture of Aspergillus, or galactomannan in respiratory samples provide supportive evidence. The diagnostic criteria for CPA are outlined in Figure 6.

The most common form of CPA is chronic cavitary pulmonary aspergillosis which occurs in non-immunocompromised patients with lung disease. When untreated, it may progress to chronic fibrosing pulmonary aspergillosis as shown in Figure 7. Less common forms of CPA are Aspergillus nodule(s) and single aspergilloma shown in Figure 8.

Sub-acute invasive aspergillosis also known as chronic necrotizing pulmonary aspergillosis. It develops over 4-12 weeks, usually affects mildly immunocompromised patients and manifests with variable radiological features including cavitation, nodules, progressive consolidation with ‘abscess formation’.

<table>
<thead>
<tr>
<th>Clinical Criteria:</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Chronic pulmonary or systemic symptoms (duration &gt; 3 months) including at least one of the following symptoms: weight loss, productive cough or hemoptysis.</td>
</tr>
<tr>
<td>• No overt immunocompromised conditions (e.g. hematological malignancy, neutropenia, organ transplantation, chronic granulomatous disease)</td>
</tr>
<tr>
<td><strong>AND</strong></td>
</tr>
<tr>
<td><strong>Radiological Criteria:</strong></td>
</tr>
<tr>
<td>• Cavitary pulmonary lesions with evidence of paracavitary infiltrates, new cavitary formation, or expansion of cavitary size over time.</td>
</tr>
<tr>
<td><strong>AND</strong></td>
</tr>
<tr>
<td><strong>Laboratory Criteria:</strong></td>
</tr>
<tr>
<td>• Either positive result of serum precipitins or IgG to <em>Aspergillus</em> or isolation of <em>Aspergillus</em> species from pulmonary or pleural cavity.</td>
</tr>
<tr>
<td>• Elevated levels of inflammatory markers (C-reactive protein, erythrocyte sedimentation rate).</td>
</tr>
<tr>
<td>• Exclusion of other pulmonary pathogens, by results of appropriate cultures and serological tests, that are associated with similar disease presentation, including mycobacteria and endemic fungi.</td>
</tr>
</tbody>
</table>

Figure 5. A schematic to illustrate the different forms of chronic pulmonary aspergillosis, in particular the overlap that is often seen – reproduced from Denning et al with permission [22].
Treatment of CPA

1. Treatment of chronic cavitary and fibrosing aspergillosis
   Patients with CPA and with pulmonary symptoms including progressive loss of lung function or radiographic progression should be treated with a minimum of 6 months of antifungal therapy [18]. Oral Itraconazole and voriconazole are the preferred oral antifungal agents; posaconazole is an alternative therapy for those with adverse effects or clinical failure. Patients with subacute invasive aspergillosis should be managed as invasive aspergillosis.

2. Treatment of simple aspergilloma
   Surgical resection is a definitive treatment for patients with adequate pulmonary function. Intracavitary instillation of amphotericin B is an effective short-term treatment to control severe hemoptysis [24]. Mild to moderate hemoptysis can be controlled with tranexamic acid that inhibits fibrinolysis of clots. Catheter embolization of the bronchial arteries may be a lifesaving procedure for severe hemoptysis, either as a temporizing measure before surgery or as a definitive treatment.

3. Treatment of Aspergillus nodule
   A single Aspergillus nodule that has been completely excised does not need antifungal treatment if the patient is immunocompetent. In immunocompromised patients, an oral azole such as oral itraconazole is indicated [3]. In a patient with multiple nodules who undergoes surgical excision of a single nodule, azole therapy is recommended and these patients require radiographic follow up with chest CT after excision of a single nodule. If the residual nodules are progressive, continued azole therapy is indicated and a repeat biopsy should be considered to rule out other etiologies [22].

Acute Community-Acquired Aspergillus Pneumonia

There appear to be 3 different presentations of community acquired Aspergillus pneumonia:

1. massive exposures to airborne Aspergillus spores that overwhelm the immunity of the lung to fight infection ('mulch pneumonitis')
2. lower levels of exposure following influenza infection
3. patients with COPD and those on chronic systemic corticosteroid therapy

Chest imaging shows a diffuse miliary pattern in cases of massive exposure, or unilateral upper-lobe cavitary disease. Aspergillosis may occur in the setting of severe influenza infections even among immunocompetent hosts and carries a mortality rate of almost 50% [25]. Diagnosis requires a high level of suspicion. Aspergillus can be isolated from optimal respiratory tract specimens (bronchoalveolar lavage and bronchial brushings) and galactomannan should be detectable in the bronchoalveolar lavage (BAL) fluid. Prompt therapy with voriconazole is recommended given the high mortality rates [26].

Aspergillus bronchitis

Aspergillus bronchitis is a chronic superficial Aspergillus infection of the bronchial tree in a non-immunocompromised patient, usually with bronchiectasis or cystic fibrosis. If the patient has significant immunocompromise (recent chemotherapy, transplantation, or AIDS) the term IA tracheobronchitis should be applied. Dr. Denning’s group proposed the following criteria for the diagnosis of chronic Aspergillus bronchitis [27].
Bronchial asthma and cystic fibrosis

Essential criteria:
• Serum A. fumigatus specific IgE levels > 0.35 kUA/L or positive type I Aspergillus skin test
• Elevated serum total IgE levels > 1000 IU/mL (an IgE value <1000 IU/mL may be acceptable if all other criteria are met, especially if the serum A. fumigatus specific IgG level > 27 mg/L)

Additional criteria (two of three must be met):
• Presence of precipitating (or IgG) antibodies against A. fumigatus in serum
• Thoracic imaging findings consistent with ABPA
  o Transient abnormalities: nodules, consolidation, mucoid impaction, hyper-attenuating mucus, fleeting opacities, toothpaste/gloved-finger opacities, or tram-track sign
  o Permanent abnormalities: parallel lines, ring shadows, bronchiectasis, pleuropulmonary fibrosis
• Historical or current peripheral blood eosinophil count > 500 cells/µL

Criteria Proposed by Agarwal et al

Essential criteria:
• Serum A. fumigatus specific IgG level > 0.35 kUA/L, (a positive type I Aspergillus skin test may be considered as a criterion in place of serum A. fumigatus specific IgE levels only if the latter test is not available)
• Elevated serum total IgE levels > 1000 IU/mL (an IgE value <1000 IU/mL may be acceptable if all other criteria are met, especially if the serum A. fumigatus specific IgG level >27 mg/L)

Additional criteria (two of three must be met):
• Serum A. fumigatus IgG level = 27 mg/L OR
• Thoracic imaging findings consistent with ABPA
  o Transient abnormalities: nodules, consolidation, mucoid impaction, hyper-attenuating mucus, fleeting opacities, toothpaste/gloved-finger opacities
  o Permanent abnormalities: parallel lines, ring shadows, bronchiectasis, pleuropulmonary fibrosis
• Historical or current peripheral blood eosinophil count > 500 cells/µL

Table 3. A table comparing the diagnostic criteria for ABPA by the ABPA Working Group and those proposed by Agarwal et al [29]. (COPD: chronic obstructive pulmonary disease; kUA: kilounit of antibody; mgA: milligram of antibody; ABPA: Allergic bronchopulmonary Aspergillosis; Ig: immunoglobulin.)

Treatment of ABPA bronchitis
Oral azole therapy (itraconazole, voriconazole, posaconazole) for 4 months is effective in the majority of patients, however, relapse risk is about 50% and these patients may need long-term therapy [27].

Allergic Bronchopulmonary Aspergillosis
ABPA is a pulmonary disorder caused by hypersensitivity to *Aspergillus fumigatus* that complicates the course of patients with asthma and cystic fibrosis. It presents with different clinical and radiological manifestations such as refractory asthma, recurrent fleeting pulmonary infiltrates with or without bronchiectasis. ABPA should be suspected in all patients with asthma and cystic fibrosis regardless of the severity or the level of disease control. A working group of 'ABPA in asthmatics' formed by the International Society of Human and Animal Mycology (ISHAM) convened an expert group that proposed new criteria for ABPA in 2015 [28]. Subsequently, Agarwal et al have recently proposed new criteria outlined in Table 3 [29]. Comparing the ABPA working group criteria to the criteria proposed by Agarwal et al, the proposed criteria include a larger array of lung disease (COPD, post-tuberculous fibrocavitary disease) and identifies a specific A. fumigatus IgG level. The diagnostic algorithm for ABPA is outlined in Figure 9.

Treatment of ABPA
ABPA has distinct stages of progression from an acute infection (stage 1) to advanced ABPA (stage 6) as listed in Table 4. The treatment of ABPA has been described by Agarwal et al [29], highlighted in the flowchart shown in Figure 10. Primary treatment of ABPA involves corticosteroids for asthma attacks associated with ABPA. The most frequently used schedule is the low-dose steroid regimen (prednisone 0.5mg/kg/day) for 5 months. Alternative treatments describe oral Itraconazole 200mg twice daily for 16 weeks or longer. Itraconazole has been shown to decrease the number of exacerbations requiring steroids with improved lung function and exercise tolerance. [30, 31] Itraconazole can eliminate *Aspergillus* in the airways and can theoretically reduce the allergic responses in ABPA. The aim of the MIPA trial (Monotherapy of Itraconazole Versus Prednisonolone in Allergic Bronchopulmonary Aspergillosis; clinicaltrials.gov ID: NCT01321827), a prospective randomized controlled trial that is currently underway, is to evaluate the efficacy and safety of itraconazole monotherapy in patients with ABPA.
Conclusions

The different clinical syndromes caused by Aspergillus can be considered as a continuous spectrum of disease resulting from the interplay of Aspergillus, host immunity and underlying lung disease. The spectrum runs from invasive pulmonary aspergillosis to Aspergillus bronchitis. One form of aspergillosis may evolve from one form into another depending of the degree of immunity of the host. Prompt diagnosis and treatment with appropriate antifungals are essential for improved outcomes.

Funding Source: No funding sources to declare.
Conflicts of Interest: The authors listed do not have any pertinent financial disclosures or conflicts of interest.

Table 4. The treatment stages of ABPA adapted from Agarwal et al [29].

<table>
<thead>
<tr>
<th>Stage</th>
<th>Definition</th>
<th>Features</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Asymptomatic</td>
<td>No previous diagnosis of ABPA Fulfills criteria for ABPA Controlled asthma per GINA guidelines</td>
</tr>
<tr>
<td>1</td>
<td>Acute ABPA</td>
<td>No previous diagnosis of ABPA Fulfills criteria for ABPA Uncontrolled asthma or symptoms consistent with ABPA</td>
</tr>
<tr>
<td>2</td>
<td>Response</td>
<td>Clinical and/or radiographic improvement AND Decline in IgE ≥ 25% of baseline at 8 weeks</td>
</tr>
<tr>
<td>3</td>
<td>Exacerbation</td>
<td>Clinical and/or radiographic worsening AND Increase in IgE ≥ 50% from baseline established during response/remission</td>
</tr>
<tr>
<td>4</td>
<td>Remission</td>
<td>Sustained clinical and radiographic improvement AND IgE levels persisting at or below baseline (or increase by &lt; 50) for ≥ 6 months off treatment</td>
</tr>
<tr>
<td>5</td>
<td>Treatment-dependent</td>
<td>Systemic glucocorticoids require for control of asthma while the ABPA activity is controlled (as indicated by IgE levels and thoracic imaging OR 2 or more exacerbations within 6 months of stopping therapy OR Worsening of clinical and/or radiographic condition with rise in IgE levels on tapering steroids</td>
</tr>
<tr>
<td>6</td>
<td>Advanced ABPA</td>
<td>Extensive bronchiectasis due to ABPS on chest imaging AND Complications such as cor pulmonale or chronic respiratory failure</td>
</tr>
</tbody>
</table>

References


